Immutep targets $100m for lung cancer drug trial tests
Immutep has launched a capital raise aiming to boost its war chest by $100 million to progress late stage trials for lung cancer sufferers.
WSS
0.00%
0.0¢
WORKING SYSTEMS SOLUTIONS LIMITED - Corporate Spotlight
Currently unlisted.
Add to my watchlist
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No Corporate Spotlight currently available.